The mechanism mentioned above may provide certain explanations for the findings that KEAP1 mutation or NRF2 activation is associated with resistance to immune checkpoint blockade therapy in lung cancer 31, 78, 91. This evidence concerns the gene KEAP1 and lung carcinoma.